Nectin-4: A New Marker for Breast Cancer
Author Information
Author(s): Fabre-Lafay Stéphanie, Monville Florence, Garrido-Urbani Sarah, Berruyer-Pouyet Carole, Ginestier Christophe, Reymond Nicolas, Finetti Pascal, Sauvan Richard, Adélaïde José, Geneix Jeannine, Lecocq Eric, Popovici Cornel, Dubreuil Patrice, Viens Patrice, Gonçalves Anthony, Charafe-Jauffret Emmanuelle, Jacquemier Jocelyne, Birnbaum Daniel, Lopez Marc
Primary Institution: Inserm, UMR599, Centre de Recherche en Cancérologie de Marseille
Hypothesis
Nectin-4 is a new histological and serological tumor-associated marker for breast carcinoma.
Conclusion
Nectin-4 is a new tumor-associated antigen for breast carcinoma that could help refine breast cancer taxonomy and improve patient follow-up.
Supporting Evidence
- Nectin-4 was expressed in 61% of ductal breast carcinoma samples.
- Nectin-4 expression correlates with basal-like markers and is absent in normal breast epithelium.
- The combination of CEA, CA15.3, and Nectin-4 improved patient monitoring from 67% to 74%.
- Serum Nectin-4 levels correlate with the number of metastases.
- Nectin-4 is a marker of therapeutic efficiency, correlating with clinical evolution in 90% of cases.
Takeaway
Nectin-4 is a special marker found in breast cancer that helps doctors track how the disease is doing and could be used to improve treatments.
Methodology
The study involved measuring Nectin-4 protein expression in breast cancer samples and serum using FACS analysis, immunohistochemistry, and ELISA.
Limitations
The study may not generalize to all breast cancer types as it primarily focused on ductal and lobular carcinomas.
Participant Demographics
The study included sera from healthy donors and patients with non-metastatic and metastatic breast carcinoma.
Statistical Information
P-Value
0.038
Statistical Significance
p=0.038
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website